Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 01/21/16 → 11/13/18 |
Funding
- Quintiles Incorporated: $19,146.80
Genentech: An Open-Label, Single-Arm, Phase II Study of Pertuzumab with High-Dose Trastuzumab for the Treatment of Central Nervous System Progression Post-Radiotherapy in Patients with Her2-Positive Metastatic Breast Cancer
- Stopeck, Alison (PI)
- Baer, Lea (CoPI)
- Cohen, Jules A (CoPI)
- Kudelka, Andrzej (CoPI)
Project: Research